Immunotherapy Keytruda for Early-Stage Triple-Negative Breast Cancer: Better pCR and Lower Recurrence Rates: ESMO 2019 Coverage
At the European Society for Medical Oncology 2019 Congress, Dr. Schmid presented results from the KEYNOTE-522 study showing that the combination of the immunotherapy Keytruda (chemical name: pembrolizumab) and chemotherapy before surgery to remove early-stage triple-negative breast cancer led to a better pathologic complete response than chemotherapy alone. This is the first phase III study using immunotherapy to treat early-stage breast cancer.
Listen to the podcast to hear Dr. Schmid discuss:
the design of the KEYNOTE-522 study
side effects related to both chemotherapy and Keytruda
what these results mean for patients
Dr. Peter Schmid is chair in cancer medicine at Barts Cancer Institute, Queen Mary University London and also serves as clinical director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and honorary consultant medical oncologist at Barts Hospital. His research focuses on breast cancer, cancer immune therapy, and early drug development.
— Last updated on February 11, 2022, 7:58 PM
This content made possible by Lilly Oncology.